Tcr2 Therapeutics Performance
| TCRRDelisted Stock | USD 1.48 0.00 0.00% |
The entity has a beta of -1.7, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Tcr2 Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Tcr2 Therapeutics is expected to outperform it. Tcr2 Therapeutics right now has a risk of 0.0%. Please validate Tcr2 Therapeutics total risk alpha, downside variance, as well as the relationship between the Downside Variance and day median price , to decide if Tcr2 Therapeutics will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Tcr2 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Tcr2 Therapeutics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 223.7 M | |
| Total Cashflows From Investing Activities | -88.5 M |
Tcr2 |
Tcr2 Therapeutics Relative Risk vs. Return Landscape
If you would invest 148.00 in Tcr2 Therapeutics on August 31, 2024 and sell it today you would earn a total of 0.00 from holding Tcr2 Therapeutics or generate 0.0% return on investment over 90 days. Tcr2 Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Tcr2, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tcr2 Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tcr2 Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tcr2 Therapeutics, and traders can use it to determine the average amount a Tcr2 Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| TCRR |
Based on monthly moving average Tcr2 Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tcr2 Therapeutics by adding Tcr2 Therapeutics to a well-diversified portfolio.
Tcr2 Therapeutics Fundamentals Growth
Tcr2 Stock prices reflect investors' perceptions of the future prospects and financial health of Tcr2 Therapeutics, and Tcr2 Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tcr2 Stock performance.
| Return On Equity | -0.91 | |||
| Return On Asset | -0.35 | |||
| Current Valuation | (73.69 M) | |||
| Shares Outstanding | 39.26 M | |||
| Price To Book | 0.22 X | |||
| EBITDA | (89.62 M) | |||
| Cash And Equivalents | 175.99 M | |||
| Cash Per Share | 4.55 X | |||
| Total Debt | 58.23 M | |||
| Debt To Equity | 0.29 % | |||
| Book Value Per Share | 2.58 X | |||
| Cash Flow From Operations | (101.46 M) | |||
| Earnings Per Share | (4.20) X | |||
| Total Asset | 208.24 M | |||
| Retained Earnings | (501.34 M) | |||
About Tcr2 Therapeutics Performance
Assessing Tcr2 Therapeutics' fundamental ratios provides investors with valuable insights into Tcr2 Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Tcr2 Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor therapies for patients suffering from cancer. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Tcr2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people.Things to note about Tcr2 Therapeutics performance evaluation
Checking the ongoing alerts about Tcr2 Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tcr2 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tcr2 Therapeutics is not yet fully synchronised with the market data | |
| Tcr2 Therapeutics may become a speculative penny stock | |
| Tcr2 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (151.82 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tcr2 Therapeutics currently holds about 175.99 M in cash with (101.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Tcr2 Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tcr2 Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Tcr2 Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tcr2 Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tcr2 Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tcr2 Therapeutics' stock. These opinions can provide insight into Tcr2 Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |